Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease (MMACKD)
The purpose of this study is to determine whether matrix metalloproteinases are associated with atherosclerosis in the different stages of chronic kidney disease.
|Study Design:||Observational Model: Case Control
Time Perspective: Cross-Sectional
|Official Title:||The Role of Matrix Metalloproteinases -2 and -9 in Atherosclerosis of Patients With Chronic Kidney Disease|
- Association of matrix metalloproteinases with atherosclerosis in patients with chronic kidney disease [ Time Frame: two years ] [ Designated as safety issue: No ]Matrix metalloproteinases associated with atherosclerosis in chronic kidney disease;patients with diabetes mellitus type 2 and others with chronic glomerulonephritis.Serum levels of MMPs-2 and -9 are measured by an ELISA system.Intima Media Thickness(IMT) of carotid and femoral arteries is measured with a high resolution ultrasonography.
- Matrix metalloproteinases and atherosclerosis associated with pro-inflammatory and oxidative stress markers in chronic kidney disease [ Time Frame: two years ] [ Designated as safety issue: No ]Matrix metalloproteinases associated with atherosclerosis markers,pro-inflammatory markers and markers of oxidative stress in chronic kidney disease
Biospecimen Retention: Samples Without DNA
serum and vessels
|Study Start Date:||October 2011|
|Estimated Study Completion Date:||May 2016|
|Estimated Primary Completion Date:||May 2016 (Final data collection date for primary outcome measure)|
Diabetic nephropathy in patients with type 2 diabetes
chronic glomerulonephritis in patients without diabetes mellitus
participants without diabetic nephropathy and chronic glomerulonephritis
The purpose of this study is to determine the correlation of matrix metalloproteinases and atherosclerosis of chronic kidney disease. Patients with diabetes mellitus type 2,as a non-inflammatory leading cause of end stage renal failure and patients with chronic glomerulonephritis and similar course of proteinuria,as an inflammatory leading cause of end stage renal failure are enrolled.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01458158
|Contact: Grigorios G. Dimas||+0030 email@example.com|
|AHEPA University Hospital, Medical School of Aristotle University of Thessaloniki||Recruiting|
|Principal Investigator: Grigorios G. Dimas, MD|
|Principal Investigator:||Grigorios G. Dimas, MD||AHEPA University Hospital,Medical School of Aristotle University of Thessaloniki|